Imvanex

Active Ingredient:: Modified Vaccinia Ankara – Bavarian Nordic Live Virus
Origin:: EU

Imvanex (Modified Vaccinia Ankara – Bavarian Nordic Live Virus)

Q: What is Imvanex used for?

Imvanex is a vaccine that contains the Modified Vaccinia Ankara (MVA) live virus. It is used to prevent infection with orthopoxviruses, specifically smallpox, monkeypox and related viruses, in individuals for whom vaccination is indicated according to public‑health or clinical guidelines.

Q: How does Modified Vaccinia Ankara work in Imvanex?

The MVA strain is a highly attenuated, replication‑deficient vaccinia virus. After subcutaneous injection it infects host cells and expresses orthopoxvirus antigens, which stimulate both antibody‑mediated (humoral) and T‑cell‑mediated (cellular) immune responses. This dual activation creates protective immunity without causing disease.

Q: What is the usual dose of Imvanex?

The dosing regimen for Imvanex is determined by the prescribing healthcare professional based on the approved label and the patient’s age, weight and risk profile. The prescriber decides the number of doses, interval and administration site; no self‑adjusted dosing is recommended.

Q: Is Imvanex safe to use during pregnancy or breastfeeding?

Safety data for Imvanex in pregnant or lactating women are limited, and the product’s pregnancy category is not established. Use during pregnancy or breastfeeding should only occur if the potential benefit justifies any potential risk, and it must be decided by a qualified healthcare provider.

Q: How do I order Imvanex from GNH India?

To request Imvanex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Q: How does Imvanex compare with other smallpox vaccines?

Imvanex uses the Modified Vaccinia Ankara strain, which is replication‑deficient and therefore has a more favorable safety profile than traditional replicating vaccinia‑based vaccines. It offers comparable immunogenicity for orthopoxvirus protection while reducing the risk of severe vaccine‑related complications, especially in immunocompromised individuals.

Q: What are the storage and handling requirements for Imvanex?

Imvanex must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Before administration, allow the product to reach room temperature if required, and inspect for any particulate matter or discoloration.

Q: How is Imvanex administered?

Imvanex is supplied as a sterile solution for subcutaneous injection. A qualified healthcare professional injects the prescribed volume into the subcutaneous tissue, typically in the upper arm or thigh, using aseptic technique. The injection site should be observed for local reactions after administration.

Q: What are the most serious risks associated with Imvanex?

The most serious adverse events reported with Imvanex include severe allergic reactions such as anaphylaxis, myocarditis, encephalitis, disseminated vaccinia infection in immunocompromised patients, and severe skin reactions like eczema vaccinatum. Prompt medical evaluation is essential if any of these symptoms develop.

Q: Who should not receive Imvanex?

Imvanex is contraindicated in individuals with known severe allergic reactions to any component of the vaccine, those with active eczema or atopic dermatitis, severely immunocompromised patients (e.g., undergoing high‑dose chemotherapy, advanced HIV with low CD4 counts), and persons who have received another live viral vaccine within the preceding four weeks.

Modified Vaccinia Ankara (MVA) live virus, the active ingredient in Imvanex, is a live viral vaccine presented as an unspecified strength/solution for subcutaneous injection use. It induces immunity to prevent smallpox, monkeypox and other orthopoxvirus infections in adults and children as indicated. The vaccine is administered as a single subcutaneous dose and is authorized for use throughout the European Union.

GNH India supplies Imvanex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution and regulatory compliance across multiple markets.

Manufacturer / TM Owner

Bavarian Nordic A/S

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Imvanex, a live viral vaccine targeting orthopoxviruses, is indicated for the following preventive uses:
Smallpox: Provides active immunity to prevent smallpox infection in individuals at risk.
Monkeypox: Confers protection against monkeypox virus exposure in endemic or outbreak settings.
Other orthopoxvirus infections: Offers cross‑protective immunity against related orthopoxviruses such as vaccinia and cowpox.
Post‑exposure prophylaxis: Can be used shortly after exposure to orthopoxviruses to reduce disease severity.

How It Works

Imvanex contains the Modified Vaccinia Ankara (MVA) virus, a highly attenuated, replication‑deficient strain of vaccinia. After subcutaneous injection, the live virus enters host cells and expresses orthopoxvirus antigens, stimulating both humoral antibody production and cellular T‑cell responses. This dual immune activation generates protective immunity against smallpox, monkeypox and related orthopoxviruses while the vaccine’s inability to replicate in human tissue enhances safety and preserves immunogenicity.

Side Effects

Imvanex may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects

Injection site pain: mild to moderate pain at the injection site lasting 1‑2 days.
Redness: localized erythema around the injection area that resolves spontaneously.
Swelling: temporary swelling at the site, usually subsiding within a few days.
Fever: low‑grade fever (≤38.5 °C) occurring within 24‑48 hours after vaccination.
Headache: mild headache reported by some recipients during the first 24 hours.
Fatigue: general tiredness that may last up to 48 hours.

Serious or Rare Side Effects

Anaphylaxis: severe allergic reaction with hives, airway swelling, requiring immediate emergency treatment.
Myocarditis: inflammation of the heart muscle, reported rarely, presenting with chest pain or shortness of breath.
Encephalitis: inflammation of the brain, a rare neurologic event that may cause seizures or altered consciousness.
Disseminated vaccinia infection: uncontrolled spread of vaccinia virus in immunocompromised individuals, leading to widespread lesions.
Severe skin reactions: such as eczema vaccinatum or generalized rash, occurring in patients with pre‑existing skin conditions.

Precautions & Warnings

Prior to administering Imvanex, healthcare professionals should observe the following precautions to ensure safety.

Assess immune status: verify the patient is not severely immunocompromised.
Contraindicate in severe eczema: avoid use in individuals with active eczema or atopic dermatitis.
Defer during acute illness: postpone vaccination if the patient has a febrile or severe infection.
Monitor cardiac symptoms: observe for chest pain or palpitations after vaccination.
Avoid concomitant live vaccines: do not co‑administer other live viral vaccines within four weeks.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Imvanex can interact with certain medicines or vaccines; awareness of these interactions helps prevent reduced efficacy or increased risk.

Major Interactions (Avoid)

High‑dose corticosteroids: suppress immune response, diminishing vaccine effectiveness.
Chemotherapy agents: profound immunosuppression may lead to uncontrolled viral replication.
Biologic immunomodulators (e.g., TNF‑α inhibitors): increase risk of adverse vaccine reactions.
HIV with CD4 <200 cells/µL: severe immunodeficiency contraindicates use.
Other live vaccines: simultaneous administration can cause interference or enhanced reactogenicity.

Moderate Interactions (Monitor Closely)

Anticoagulants: may increase risk of bleeding at the injection site.
Antipyretics (e.g., acetaminophen) taken prophylactically: could blunt antibody response if used before vaccination.
Immunoglobulin therapy: may neutralize vaccine virus if given shortly before or after vaccination.

Frequently Asked Questions

Imvanex is a vaccine that contains the Modified Vaccinia Ankara (MVA) live virus. It is used to prevent infection with orthopoxviruses, specifically smallpox, monkeypox and related viruses, in individuals for whom vaccination is indicated according to public‑health or clinical guidelines.

The MVA strain is a highly attenuated, replication‑deficient vaccinia virus. After subcutaneous injection it infects host cells and expresses orthopoxvirus antigens, which stimulate both antibody‑mediated (humoral) and T‑cell‑mediated (cellular) immune responses. This dual activation creates protective immunity without causing disease.

The dosing regimen for Imvanex is determined by the prescribing healthcare professional based on the approved label and the patient’s age, weight and risk profile. The prescriber decides the number of doses, interval and administration site; no self‑adjusted dosing is recommended.

Safety data for Imvanex in pregnant or lactating women are limited, and the product’s pregnancy category is not established. Use during pregnancy or breastfeeding should only occur if the potential benefit justifies any potential risk, and it must be decided by a qualified healthcare provider.

To request Imvanex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Imvanex uses the Modified Vaccinia Ankara strain, which is replication‑deficient and therefore has a more favorable safety profile than traditional replicating vaccinia‑based vaccines. It offers comparable immunogenicity for orthopoxvirus protection while reducing the risk of severe vaccine‑related complications, especially in immunocompromised individuals.

Imvanex must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Before administration, allow the product to reach room temperature if required, and inspect for any particulate matter or discoloration.

Imvanex is supplied as a sterile solution for subcutaneous injection. A qualified healthcare professional injects the prescribed volume into the subcutaneous tissue, typically in the upper arm or thigh, using aseptic technique. The injection site should be observed for local reactions after administration.

The most serious adverse events reported with Imvanex include severe allergic reactions such as anaphylaxis, myocarditis, encephalitis, disseminated vaccinia infection in immunocompromised patients, and severe skin reactions like eczema vaccinatum. Prompt medical evaluation is essential if any of these symptoms develop.

Imvanex is contraindicated in individuals with known severe allergic reactions to any component of the vaccine, those with active eczema or atopic dermatitis, severely immunocompromised patients (e.g., undergoing high‑dose chemotherapy, advanced HIV with low CD4 counts), and persons who have received another live viral vaccine within the preceding four weeks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 08 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.